Introduction Etelcalcetide is a novel intravenous calcimimetic for the treatment of secondary hyperparathyroidism (SHPT) in haemodialysis patients. The clinical efficacy and safety of etelcalcetide (in addition to phosphate binders and vitamin D and/or analogues [PB/VD]) was evaluated in three phase III studies, including two placebo-controlled trials and a head-to-head study versus the oral calcimimetic cinacalcet.
Objective The objective of this study was to develop a decision-analytic model for economic evaluation of etelcalcetide compared with cinacalcet. Methods We developed a life-time Markov model including potential treatment effects on mortality, cardiovascular events, fractures, and subjects' persistence. Longterm efficacy of etelcalcetide was extrapolated from the reduction in parathyroid hormone (PTH) in the phase III trials and the available data from the outcomes study in cinacalcet (EVOLVE trial). Etelcalcetide was compared with cinacalcet, both in addition to PB/VD. We applied unit costs averaged from five European countries and a range of potential etelcalcetide pricing options assuming parity price to weekly use of cinacalcet and varying it by a 15 or 30% increase. Results Compared with cinacalcet, the incremental costeffectiveness ratio of etelcalcetide was €1,355 per QALY, €24,521 per QALY, and €47,687 per QALY for the three prices explored. The results were robust across the probabilistic and deterministic sensitivity analyses. Conclusions Our modelling approach enabled cost-utility assessment of the novel therapy for SHPT based on the observed and extrapolated data. This model can be used for local adaptations in the context of reimbursement assessment.
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Introduction and Objective
Secondary hyperparathyroidism (SHPT) is a disease characterized by the excessive secretion of parathyroid hormone (PTH) and is associated with hyperplasia of the parathyroid glands. This disorder is a common complication in patients with chronic kidney disease (CKD) on haemodialysis. SHPT is linked to the risk of extra skeletal calcification, reduced bone density and strength [1] , bone fractures [2] , and morbidity and mortality [3] [4] [5] . The prevalence of SHPT within the dialysis population ranges between 30 and 49% in Europe and Australia and is estimated at about 54% in North America [6] . The traditional treatment of SHPT includes treatment with active forms of vitamin D or its analogues and phosphate binders. In past years, cinacalcet, the first calcimimetic agent, has been established as an additional effective therapy for this indication. For patients with severe SHPT who do not respond adequately to medical therapy, surgical removal of parathyroid glands (parathyroidectomy [PTx] ) is also a viable option. The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (K/DOQI), has established clinical practice guidelines for bone metabolism and disease in CKD. These clinical practice guidelines also specify target levels of PTH, serum calcium, and serum phosphorus [7] .
Etelcalcetide is a novel D-amino peptide calcimimetic approved in the EU and USA for the treatment of SHPT in adult haemodialysis patients. Etelcalcetide is administered intravenously three times per week at the end of each dialysis session. This route of administration, from the patient perspective, has been shown to be more convenient (preferred) over oral administration [8] . Etelcalcetide is an allosteric activator that binds to, and activates, the calciumsensing receptors in the parathyroid gland, resulting in reduced PTH secretion. The efficacy of etelcalcetide in reducing PTH levels has been established by three phase III studies, two parallel placebo-controlled trials [9] , and a head-to-head study comparing etelcalcetide against cinacalcet [10] . In the head-to-head study, etelcalcetide met the primary endpoint of non-inferiority, measured as the proportion of patients achieving a[30% PTH reduction from baseline during the efficacy assessment phase, and the secondary endpoints of superiority ([50 and[30% reduction in PTH).
The objective of this study was to develop a decisionanalytic model for economic evaluation of etelcalcetide compared with cinacalcet. We expect this model can be adapted to local settings and will be applied to inform reimbursement decisions.
Methods
We developed a Markov cohort state transition model using a 3-month cycle length and a life-time horizon. We followed the current best practice modelling and reporting guidelines [11, 12] and considered previously published cinacalcet cost-effectiveness models as a context [13, 14] . We conducted model validation based on the AdViSHE validation tool (see the electronic supplementary material [ESM]) [15] . We also applied a life-table half-cycle correction [16, 17] . Both costs and outcomes were discounted at an annual rate of 3%. Treatment with etelcalcetide was compared with treatment with cinacalcet. Both calcimimetics were assumed to be administered in addition to phosphate binders and vitamin D, or its analogues (PB/ VD). As an option, we explored the comparison of etelcalcetide with 'no calcimimetics' (i.e. PB/VD alone), which would represent a clinical decision to use etelcalcetide after cinacalcet discontinuation (see the ESM). The characteristics of the model population were aligned with etelcalcetide trials [9, 10] and the EVOLVE (EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events) trial [18] . EVOLVE was a global, multi-centre, placebo-controlled, double-blind, event-driven trial that assessed the impact of cinacalcet on outcomes in an SHPT dialysis population [18] . The primary endpoint was a composite of all-cause mortality and major cardiovascular (CV) events. Other clinical events such as fractures and PTx were registered as secondary endpoints [18, 19] . EVOLVE is the only long-term randomized controlled trial to directly measure the impact of calcimimetics on SHPT clinical outcomes. Figure 1 shows the design of the model. Simulated subjects entered the model in the 'event-free' state. During the simulation, subjects could experience CV events and fractures as a consequence of the disease or die. Subjects who did not persist with calcimimetic treatment switch to PB/VD alone. Lastly, the occurrence of PTx was simulated because this event can generate costs and short-term health consequences.
The decision model compares long-term outcomes (survival and quality-adjusted life-years [QALYs]) and overall costs. Calcimimetic treatment results in more controlled levels of SHPT biomarkers (PTH, serum calcium, and phosphorus), which are related to mortality and the incidence of CV events, fractures, and PTx. The efficacy compared with 'no calcimimetic treatment' was parameterized as a hazard ratio (HR) by type of event (i.e. allcause mortality, non-fatal CV events, fractures, and PTx). Rates of clinical events while receiving calcimimetic treatment were obtained by applying HRs to the baseline rates (no calcimimetic treatment) (Table 1) [18, 20] .
The HRs for cinacalcet compared with 'no calcimimetics' were derived from EVOLVE [18] based on the event-specific HRs published by Belozeroff et al. [13] . Among the reported HRs, the lag-censored estimates (6-month lag) were most consistent with our model structure. This is because both the model structure and the censoring approach distinguish between subjects on versus off treatment. The EVOLVE pre-specified 6-month lag in the referenced source accounts for the delay between the drug intake and the treatment effect. As a sensitivity analysis to using lag-censored HRs, we presented an intention-to-treat (ITT)-based approach (see the ESM).
No study has measured the incidence of clinical events in patients with SHPT treated with etelcalcetide. Therefore, the cinacalcet efficacy was extrapolated based on the ability to lower PTH (see the ESM). The extrapolation was used separately for each type of event (i.e. mortality, CV events, fractures, and PTx) and was based on the primary outcome of the etelcalcetide trial (i.e. the ability of the treatment to achieve a PTH reduction of at least 30% compared with baseline). More specifically, the proportion of subjects achieving the 30% PTH reduction was calculated separately for each treatment arm (etelcalcetide, cinacalcet, and placebo) across three etelcalcetide trials. Because the HR for cinacalcet is known for each event type, we used placebo as a reference and applied the share of subjects that met the primary endpoint to approximate the efficacy of etelcalcetide.
The treatment effect in the model was applied as long as subjects continued with the calcimimetic treatments. As soon as subjects discontinued, the baseline incidence rates were applied. Consequently, on a population basis, the treatment effect of the calcimimetic treatment faded out continuously.
We modelled discontinuation with a parametric Weibull function (see the ESM). For the base case, we used US real-world data [21] . To test the sensitivity of the model to persistence assumptions, we applied EVOLVE trial persistence as an upper bound and the lowest observed realworld persistence in Europe as a lower bound (1-year persistence: EVOLVE 73%, USA 27%, France 27%, Germany 22%, Italy 16%). Given that no significant persistent difference (p = 0.60) was observed within the headto-head trial, the same discontinuation probabilities were applied for both calcimimetics. The utility values (EuroQoL 5-Dimensions [EQ-5D], Dolan algorithm) for each of the health states in the model were derived from a published EVOLVE analysis [22] using separate estimates for myocardial infarction, hospitalization for unstable angina, heart failure, and peripheral vascular event. To derive a combined utility estimate for CV events, the number of events in EVOLVE were used for weighting. The corresponding standard error was derived via error propagation [23] .
The cost perspective of the third-party payer was applied; the total cost was estimated as the sum of drug consumption, management of clinical events, and routine monitoring. Dosing for calcimimetics was quantified based on the efficacy-assessment phase of the head-to-head trial [10] . Consistent with the modelling approach from Garside et al. [14] , the same background PB/VD drug usage was assumed for all treatment strategies (Table 2) .
To parameterize this generic cost-effectiveness model, we applied crude averages of published drug prices and event costs across five European countries (Italy, Spain, Portugal, Switzerland, Czech Republic) [24] . These illustrative costs refer to the year 2010. Three potential etelcalcetide pricing scenarios were illustrated: (1) same weekly calcimimetic drug cost (WCDC), (2) 15% higher WCDC ('?15% WCDC'), and (3) 30% higher WCDC ('? 30% WCDC'). We used the weekly costs because the frequency of administration differs between calcimimetics. The ratio of average drug usage was taken for price calculation.
To assess the robustness of the model, a probabilistic sensitivity analysis was conducted with key parameters varied simultaneously in 1000 replications. The parameters of the uncertainty distributions were based on the point estimate and the standard error or confidence interval. The uncertainty of the primary endpoint of the etelcalcetide trials was sampled via the bootstrap approach. HRs of the cinacalcet treatment effect based on the EVOLVE trial were sampled via the Log-normal distribution. Baseline event rates were sampled via the Gamma distribution. Persistence adjustment and extrapolation of efficacy based on the primary endpoint in the etelcalcetide study was recalculated for the sampled values. The Gamma distribution was also applied to sample resource usage and costs. Utility decrements were sampled based on the Normal distribution, whereas absolute utility values were sampled based on the Beta distribution. The results of the probabilistic sensitivity analysis were displayed as a scatter plot on the cost-effectiveness plane and as cost-effectiveness acceptability curves.
We conducted a deterministic sensitivity analysis (DSA), where parameters were varied to the upper and lower bound of their 95% confidence intervals. For grouped parameters, or parameters without available standard errors (i.e. age-specific mortality, utility decrements, event costs, monitoring costs), we applied ± 20% of the point estimate. The results of the DSA were displayed via a tornado diagram.
We performed structural sensitivity analyses, including a different approach to estimate the treatment effect (i.e. ITT HRs), and different sources to quantify discontinuation. Lastly, to assess the uncertainty due to PTx, we included a scenario where the PTx incidence rate was set to zero.
Results
Lifetime total costs and outcomes by treatment are reported in Table 3 . Etelcalcetide was more effective, providing 0.032 additional discounted QALYs than cinacalcet. This limited QALY gain reflects the high calcimimetic discontinuation rate. If the weekly calcimimetic treatment costs were constant, the increased life expectancy resulted in a cost increase of €49. If a price mark-up was allowed, a 30% cost increase, combined with the effect of increased life expectancy, resulted in additional costs of €1518 compared with cinacalcet. These incremental costs are based on the assumption that no additional administration costs are associated with etelcalcetide treatment (Table 3) .
Compared with cinacalcet, the incremental cost-effectiveness ratio (ICER) of etelcalcetide was €1355 per QALY, €24,521 per QALY, and €47,687 per QALY for the three pricing options explored.
In the probabilistic sensitivity analysis, etelcalcetide consistently yielded more QALYs than cinacalcet (Fig. 2) .
The tornado plot of the DSA is displayed in Fig 3 ( for illustration purposes based on an increase of 15% of weekly calcimimetic treatment costs). The parameters with the highest impact on the ICER were the calcimimetic doses and the HR (etelcalcetide vs. cinacalcet) to reduce mortality. The order of these variables varied by pricing assumption. Other inputs with a high impact on outcomes were the HRs on CV events, fractures, and PTx.
The results of the structural sensitivity analyses are displayed in Table 4 . Greater persistence led to increased ICERs. This is because the treatment costs were equal at the later stages of the Markov model, but the expected QALYs gained per event avoided decreased. When the PTx rate was set to zero, the ICER slightly increased. Incorporating ITT efficacy into the model resulted in a greater ability of etelcalcetide to reduce events. This is because of the implicit assignment of the spill-over treatment effect post-discontinuation to the treatment period. For the ? 15 and ? 30% treatment scenarios, this resulted in slightly improved ICERs. For the pricing scenario where the weekly calcimimetic treatment costs did not differ between calcimimetics, the reduced mortality shifted people into later lifetime cycles, where-at similar costs to avoid one event-the QALYs per event avoided decreased, resulting in a slight increase of the ICER. 
Discussion
We developed a model to assess the cost effectiveness of etelcalcetide versus cinacalcet. The rationale for selecting cinacalcet as the comparator was that it is the current standard of care in most settings. The purpose of this article was not to calculate the cost effectiveness of etelcalcetide itself. Nor did we intend to calculate how effective etelcalcetide would have to be for a given price and a given willingness-to-pay (WTP) threshold. The efficacy of cinacalcet was directly based on the hard outcome trial EVOLVE. In contrast, though based on a randomized trial, the efficacy of etelcalcetide was extrapolated via a surrogate parameter. No hard outcomes study directly comparing etelcalcetide with cinacalcet exists, and nor do any observational studies; this is because the therapy is just entering the market. Thus, for the lifetime analysis, the decision analytic model had to rely on surrogate parameters and efficacy extrapolation. However, this is usual practice for economic analyses and is also very common in the context of dialysis care, where hard outcomes trials are very rare: Among eight previous studies reporting on the economics of SHPT treatment [13, 14, 20, [24] [25] [26] [27] [28] all but two [13, 28] used surrogate parameters. However, as the treatment effect is an explicit input to our model, the model can easily be updated once alternative estimates become available.
The efficacy estimates in this publication were based on the lag-censored approach. Though not in the context of cost-effectiveness analysis, the usage of lag-censored estimates has been questioned [29] , and the ITT approach may be preferable, particularly to assess whether a drug has a treatment effect. However, in the context of economic analyses, the purpose is to provide a point estimate of cost effectiveness. The ITT-based HRs are inconsistent with the model structure. Still, we found that, compared with the ITT sensitivity analysis, the lag-censored estimates were more conservative. This is because the lag-censored HRs A limitation of the analysis is that the treatment effect does not vary by patient characteristics such as age. Assuming constant HRs over a wide range of potential subpopulations is a common approach in decision analytic modelling and is also often assumed in meta-analyses. In the current case, we applied the published efficacy estimates based on the EVOLVE trial. No robust evidence exists that could be used to quantify a treatment effect by population subgroup. Furthermore, subgroup analyses also reduce the sample size, which makes it harder to detect significant differences.
The current model was inspired by three previous cinacalcet cost-effectiveness models [13, 14, 26] . Our definitions of health states and clinical events is generally consistent with these models. However, in the UK National Institute for Health and Care Excellence (NICE) PenTAG model [14] , PTx affects PTH levels and thus indirectly the incidence of fractures and CV events. In our model, aligned with the other two analyses [13, 26] , PTx only affected the estimation of costs and quality of life. As we outline, this choice was based on the large uncertainty of PTx outcome data.
Furthermore, in contrast to previous models, the etelcalcetide model explicitly simulated discontinuation. This is important because real-world studies on cinacalcet discontinuation have demonstrated that persistence is a key factor in the success of calcimimetic treatment. Based on the phase III trial data, we assumed the same persistence for both calcimimetics. However, in the real world, because of intravenous administration and the potential improvements in gastrointestinal events, persistence may be better for etelcalcetide.
We applied the third-party payer perspective in our illustration of this cost-effectiveness model. For some settings, the considered corresponding costs may have limitations. In particular, for some settings, it may be relevant to also consider patients' out-of-pocket costs or costs of administration.
This model assigned an equal probability of PTx to all possible transition states. A more complex model could have explicitly distinguished whether subjects could tolerate calcimimetic therapy or accounted for potential associations between the risk of fracture, CV events, and PTx. Furthermore, a short-term utility decrement is accrued after PTx, but PTx was not modelled to reduce the risk of future complications and mortality. However, such decision rules would have not only increased model complexity but also required robust input data for quantification. Increasing model complexity beyond the level of available inputs does not increase the accuracy of the results, and greater complexity often leads to criticism. The available data on the consequences of PTx are very limited: no clinical trial has compared the effectiveness of PTx and calcimimetics. Furthermore, PTx does not automatically lead to discontinuation of calcimimetics [30] .
In this model, we followed the established approach of not including dialysis costs [13, [31] [32] [33] . Dialysis per se is not a cost-effective procedure, and the inclusion of its high costs tends to drive the outcome of cost-effectiveness analyses so that even low-priced therapies might end up with high ICERs just because they extend life.
The results of the presented cost-effectiveness analysis strongly depend on the price of the innovative drug. This is not uncommon, particularly if alternative treatments are already on the market. However, it may be difficult to conclude an appropriate price for etelcalcetide from the results. That said, the purpose of this article was not to suggest a reasonable price, rather to present an economic model that can be adapted to various settings. In this context, we also highlight that substantial input parameters may differ between countries. For example, drug and event costs have been observed to be higher in the USA than in European settings [13, 26] .
Conclusions
Within the limits of the modelling approach, we created a model that could be used to assess the cost effectiveness of etelcalcetide. The cost effectiveness of etelcalcetide itself may depend on country settings, such as country-specific prices, further model inputs, and WTP. ICER incremental cost-effectiveness ratio, ITT intention to treat, QALY quality-adjusted life-year, WCDC weekly calcimimetic drug cost
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